Chondrial Therapeutics

protein replacement therapy, intracellular delivery, fusion proteins

deliverydeliveringbiologic

chondrialtherapeutics.com·Bala Cynwyd, Pennsylvania, United States·Public·$60M total funding

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-P8XL

Summary · Eternal Search editorial

Chondrial Therapeutics protein replacement therapy, intracellular delivery, fusion proteins

Larimar Therapeutics is based in the Philadelphia area and is developing treatments for complex rare diseases, with an initial focus on Friedreich's ataxia. Its proprietary protein replacement therapy platform is intended to deliver missing proteins inside cells. Its lead candidate, nomlabofusp, previously known as CTI-1601, is being evaluated in a Phase 2 clinical program for Friedreich's ataxia.

The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong

Plate C·01 · Scientific profile

All 16 dimensions
on the record.

Composite41

Chain scale100 pts

Dimensions16

Plate C·02 · Where it sits among peers

Score vs. proximity
to longevity goals.

Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.

Reading

Chondrial Therapeutics — Translational · Lower middle. Derived deterministically from 4 extracted project(s). Most-advanced status: phase 2. Band: translational. Aging-relevance not LLM-reviewed in this pass.

Source: Deterministic

At a glance

Webchondrialtherapeutics.com

HQBala Cynwyd, Pennsylvania, United States

StagePublic

Publications

14 on file

012026Nomlabofusp Treatment Produces Frataxin Levels That Correlate Across Peripheral Tissues: Preclinical and Clinical Support for Surrogate Tissue Sampling.Clinical and translational science 022026Nomlabofusp Treatment Produces Frataxin Levels That Correlate Across Peripheral Tissues: Preclinical and Clinical Support for Surrogate Tissue Sampling—0320252024 White Paper on Recent Issues in Bioanalysis: Evolution of Immunogenicity Assessment beyond ADA/NAb; Regulated Genomic/NGS Assays; Hypersensitivity Reactions; Minimum Noise Reduction; False Positive Range; Modernized Vaccine Approaches; NAb/TAb Correlation (PART 3A - Recommendations on Advanced Strategies for Molecular Assays and Immunogenicity of Gene Therapy, Cell Therapy, Vaccine; Biotherapeutics Immunogenicity Assessment & Clinical Relevance PART 3B - Regulatory Agencies' Input on Immunogenicity/Technologies of Biotherapeutics, Gene, Cell & Vaccine Therapies).Bioanalysis 042025Pharmacokinetics and Pharmacodynamics of Nomlabofusp in Non-clinical Studies of Friedreich's Ataxia.The AAPS journal 052025Pharmacokinetics and Pharmacodynamics of Nomlabofusp in Non-clinical Studies of Friedreich's Ataxia—062025Nomlabofusp, a Fusion Protein of Human Frataxin and a Cell Penetrant Peptide, Delivers Mature and Functional Frataxin into Mitochondria—072024Safety, pharmacokinetics, and pharmacodynamics of nomlabofusp (CTI-1601) in Friedreich's ataxia.Annals of clinical and translational neurology 082024Disease characteristics and tissue frataxin concentrations in adults with Friedreich's ataxia participating in nomlabofusp interventional studies—092024Prediction of tissue frataxin levels with long term administration of nomlabofusp in adults with Friedreich's ataxia using modeling and simulations—102024Effect of nomlabofusp administration on tissue frataxin levels, plasma lipid profiles, and gene expression in patients with Friedreich's ataxia—

112023Safety, pharmacokinetics, and pharmacodynamics of nomlabofusp (CTI-1601) in Friedreich's ataxia—

122012A TAT-Frataxin fusion protein increases lifespan and cardiac function in a conditional Friedreich's ataxia mouse model—

132011Cardiomyopathy of Friedreich's Ataxia Use of Mouse Models to Understand Human Disease and Guide Therapeutic Development—

142010A rapid, noninvasive immunoassay for frataxin: Utility in assessment of Friedreich ataxia—

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence

Chondrial Therapeutics

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

Loading

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.